



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: December 14, 2006 Signature: 

(Katherine L. Neville)


Docket No.: 28113/39467A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Kari Alitalo et al.

Application No.: 10/567,630

Confirmation No.: 2853

Filed: February 8, 2006

Art Unit: Not Yet Assigned

For: MATERIALS AND METHODS FOR
COLORECTAL CANCER SCREENING,
DIAGNOSIS, AND THERAPY

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 28113/39467A. A copy of this paper is enclosed.

Dated: December 14, 2006

Respectfully submitted,

By 

Katherine L. Neville

Registration No.: 53,379

MARSHALL, GERSTEIN & BORUN LLP

233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Agent for Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/567,630-Conf. #2853
				Filing Date	February 8, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	28113/39467A

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-4,946,778	08-07-1990	Ladner et al.	
	A2	US-5,093,246	03-03-1992	Cech et al.	
	A3	US-5,116,742	05-26-1992	Cech et al.	
	A4	US-5,225,337	07-06-1993	Robertson et al.	
	A5	US-5,254,678	10-19-1993	Haseloff et al.	
	A6	US-5,939,598	08-17-1999	Kucheralapati et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO 00/32765	06-08-2000	Immusol, Inc.		
	B2	WO 90/07641	07-12-1990	Sundstrand Corporation		
	B3	WO 93/23569	11-25-1993	Ribozyme Pharmaceuticals, Inc.		
	B4	WO 94/02602	02-03-1994	Cell Genesys, Inc.		
	B5	WO 96/33735	10-31-1996	Cell Genesys, Inc.		
	B6	WO 96/34096	10-31-1996	Cell Genesys, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Artavanis-Tsakonas, <i>Science</i> , Vol. 284, pp.770-776 (1999).	
	C2	Bach et al., <i>Carcinogenesis</i> , Vol. 21, pp.469-476 (2000).	
	C3	Bange et al., <i>Cancer Res.</i> , Vol. 62, pp.840-847 (2002).	
	C4	Brummelkamp et al., <i>Science</i> , Vol. 296, pp.550-553 (2002).	
	C5	Cavallaro et al., <i>Nat. Cell Biol.</i> , Vol. 3, pp.650-657 (2001).	
	C6	Chowrira et al., <i>Nucleic Acids Res.</i> , Vol. 20, pp.2835-2840 (1992).	
	C7	Cote et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 80, pp.2026-2030 (1983).	
	C8	Daubendiek et al., <i>Nat. Biotechnol.</i> , Vol. 15, No. 3, pp.273-277 (1997).	
	C9	Elbashir et al., <i>Genes Dev.</i> , Vol. 15, pp.188-200 (2001).	
	C10	Elbashir et al., <i>Nature</i> , Vol. 411, pp.494-498 (2001).	
	C11	Fawell et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 91, pp.664-668 (1994).	
	C12	Ferkol et al., <i>FASEB J.</i> , Vol. 7, pp.1081-1091 (1993).	
	C13	Fingel et al., "The Pharmacological Basis of Therapeutics," Ch. 1, pp.1 (1975).	
	C14	Fire et al., <i>Nature</i> , Vol. 391, pp.806-811 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/567,630-Conf. #2853
				Filing Date	February 8, 2006
				First Named Inventor	Kari Alitalo
				Art Unit	Not Yet Assigned
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	28113/39467A

C15	Fujimori et al., <i>J. Biol. Chem.</i> , Vol. 278, pp.6018-6026 (2003).	
C16	Giles et al., <i>Biochem. Biophys. Acta.</i> , Vol. 1653, pp.1-24 (2003).	
C17	Gupta et al., <i>Nat. Rev. Cancer</i> , Vol. 1, pp.11-21 (2001).	
C18	Hong et al., <i>Dev. Dyn.</i> , Vol. 225, pp.351-357 (2002).	
C19	Hutvagner et al., <i>Science</i> , Vol. 297, pp.2056-2060 (2002).	
C20	Jensen et al., <i>Nat. Genet.</i> , Vol. 24, pp.36-44 (2000).	
C21	Jordan et al., <i>J. Clin. Invest.</i> , Vol. 104, pp.1061-1069 (1999).	
C22	Joutel et al., <i>Nature</i> , Vol. 383, pp.707-710 (1996).	
C23	Kaneda et al., <i>Science</i> , Vol. 243, pp.375-378 (1989).	
C24	Kato et al., <i>J. Biol. Chem.</i> , Vol. 266, pp.3361-3364 (1991).	
C25	Kawasaki et al., <i>Nature</i> , Vol. 423, pp.838-842 (2003).	
C26	Koizumi et al., <i>Nucleic Acid Res.</i> , Vol. 17, pp.7059-7071 (1989).	
C27	Kurreck et al., <i>Nucleic Acids Res.</i> , Vol. 30, pp.1911-1918 (2002).	
C28	Ladner et al., <i>Cancer Research</i> , Vol. 60, pp.3493-3503 (2000).	
C29	Lee et al., <i>Natl. Biotechnol.</i> , Vol. 20, pp.500-505 (2002).	
C30	Li et al., <i>Nature Genet.</i> , Vol. 16, pp.243-251 (1997).	
C31	Lima et al., <i>J. Biol. Chem.</i> , Vol. 272, pp.626-638 (1997).	
C32	Long et al., <i>FASEB J.</i> , Vol. 7, pp.25-30 (1993).	
C33	Martinez et al., <i>Cell</i> , Vol. 110, pp.563-574 (2002).	
C34	Morrison et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 81, pp.6851-6855 (1984).	
C35	Nagahara et al., <i>Nature Medicine</i> , Vol. 4, pp.1449-1452 (1998).	
C36	Nicolau et al., <i>Methods Enzymol.</i> , Vol. 149, pp.157-176 (1987).	
C37	Ojwang et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 89, pp.10802-10806 (1992).	
C38	Palmer et al., <i>J. Cell Biol.</i> , Vol. 154, pp.369-387 (2001).	
C39	Perales et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 91, pp.4086-4090 (1994).	
C40	Perrotta et al., <i>Biochem</i> , Vol. 31, pp.16-17 (1992).	
C41	Petrova et al., <i>Embo J.</i> , Vol. 21, pp.4593-4599 (2002).	
C42	Quaroni et al., <i>Am. J. Physiol. Cell. Physiol.</i> , Vol. 279, pp.C1045-1057 (2000).	
C43	Schwarze et al., <i>Science</i> , Vol. 285, pp.1569-1572 (1999).	
C44	Sosa-Pineda et al., <i>Nat. Genet.</i> , Vol. 25, pp.254-255 (2000).	
C45	Symons, <i>Ann. Rev. Biochem.</i> , Vol. 61, pp.641 (1992).	
C46	Takeda et al., <i>Nature</i> , Vol. 314, pp.452-454 (1985).	
C47	Tomita et al., <i>Cancer Res.</i> , Vol. 52, pp.6840-6847 (1992).	
C48	Tuschl, <i>Nat. Biotechnol.</i> , Vol. 20, pp.446-448 (2002).	
C49	Usman et al., <i>Current Opin. Struct. Biol.</i> , Vol. 6, pp.527-533 (1996).	
C50	van de Wetering et al., <i>Cell</i> , Vol. 111, pp.241-250 (2002).	
C51	White et al., <i>Cancer Res.</i> , Vol. 62, pp.1669-1675 (2002).	
C52	Wigle et al., <i>Cell</i> , Vol. 98, pp.769-778 (1999).	
C53	Wigle et al., <i>Nat. Genet.</i> , Vol. 21, pp.318-33 (1999).	
C54	Yamada et al., <i>Neurol Res.</i> , Vol. 24, pp.244-248 (2002).	
C55	Yang et al., <i>Cancer Res.</i> , Vol. 61, pp.565-569 (2001).	
C56	Yang et al., <i>Science</i> , Vol. 294, pp.2155-2158 (2001).	
C57	Yu et al., <i>Proc. Natl. Acad. Sci. (USA)</i> , Vol. 99, pp.6047-6052 (2002).	
C58	Zeng et al., <i>Mol. Cell</i> , Vol. 9, pp.1327-1333 (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



Application No. (if known): 10/567,630

Attorney Docket No.: 28113/39467A

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on December 14, 2006
Date

Signature

Katherine L. Neville

Typed or printed name of person signing Certificate

53,379
Registration Number, if applicable

(312) 474-6632
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (70 References) (2 pages)